A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Thrombotic events, AKI, and hemolytic events were rare among patients with CIDP receiving IVIG. There were no consistently different outcome risks between patients receiving GGL versus other IVIGs with US approval for CIDP.
Authors
- Mary S. Anthony (ORCID: https://orcid.org/0000-0002-5201-1794)
- J. Bradley Layton (ORCID: https://orcid.org/0000-0003-0994-5820)
- Colin Anderson‐Smits (ORCID: https://orcid.org/0000-0002-2734-6154)
- Bilal Khokhar (ORCID: https://orcid.org/0000-0003-0143-1390)
- Jie Zhou (ORCID: https://orcid.org/0000-0003-0755-4818)
- L. Michelle Bennett (ORCID: https://orcid.org/0000-0001-7120-2126)
- William Spalding (ORCID: https://orcid.org/0000-0002-2950-2931)
- Hakan Ay (ORCID: https://orcid.org/0000-0002-9146-0218)
- Zhongwen Huang
Institutions
- RTI Health Solutions (US)
- Takeda (United States) (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/pds.70124
- Citations
- 2
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Takeda Pharmaceuticals International